Corvus Pharmaceuticals (CRVS) Q3 2024 earnings summary

Executive summary

• Lead candidate soquelitinib is in Phase III for relapsed PTCL and Phase I for atopic dermatitis, with both trials progressing and interim data for atopic dermatitis expected December 2024.

• Pipeline includes ciforadenant and mupadolimab in oncology and immunology, with ongoing collaborations and new data presentations planned for 2025.

• No product revenue to date; operations funded by equity offerings, including a $30.3M direct offering in May 2024 and warrant exercises.

• Upcoming milestones include data for atopic dermatitis and systemic sclerosis, and initiation of a solid tumor trial in early 2025.

• New three-year lease for South San Francisco facility begins February 2025.

Financial highlights

• Q3 2024 net loss was $40.2 million, mainly due to a $32.8 million non-cash loss from warrant liability revaluation.

• Research and development expenses for Q3 2024 were $5.2 million, up from $4 million in Q3 2023, driven by higher clinical trial costs.

• Total operating expenses for Q3 2024 were $7.3 million, up from $5.6 million in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $41.7 million as of September 30, 2024, with $5.9 million added from warrant exercises in October 2024.

• Projected full-year 2024 net cash used in operations is $25–26 million, with year-end cash expected at $38–39 million.

Outlook and guidance

• Cash runway, including recent warrant exercise, extends into 2026 based on current plans; additional capital will be needed for full development and commercialization.

• Key milestones for 2024-2025: interim Phase I atopic dermatitis data in December 2024, preclinical systemic sclerosis data in November 2024, and phase II solid tumor trial initiation in early 2025.

• Company anticipates continued operating losses and negative cash flows for the foreseeable future.